The New DTx Business Case: Why & How International Digital-Health Solutions Pay Off
summary
The session explains how Germany’s DiGA regulatory framework makes the country a launchpad for international digital therapeutics (DTx) and describes why investing in DiGA pathways can be profitable. It outlines a blueprint for a “new generation” of European DTx companies—tightly networked with pharma and MedTech—and discusses business models and practical approaches for market entry and sustainable monetization both inside and outside the DiGA system.
AI-written summary · about
chapters (9)
- 0:00DTx introduction
- 3:13Investors and trends
- 7:47Cost and timeline
- 16:29Regulatory manufacturing
- 21:24DTx for pharma/medtech
- 29:12Legal risks
- 33:53BfArM listing
- 40:10Investor perspective
- 43:20Q&A
related talks
31mDigitally Future-Proof – Strategies for Germany as a Business Location
47mStartup Pitch by DEHubs
15mWelcome Keynote
28mRise and Fall: What Are the Success Factors for AgTech Startups in Germany?
21mShaping Europe’s Future: Unlocking Talent, Driving Innovation, Leading Transformation
31mCreating digital innovation clusters in Europe
43mFinancing Growth & Venture
16mNext Level DKB: Transformation as the Key to Sustainable Success in the Financial Market